published meta-analysis   sensitivity analysis   studies

Immunostimulants drugs in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsConPlas-19, 2020 0.56 [0.20; 1.57] DAWN-Plasma, 2021 0.61 [0.24; 1.55] NCT04397757, 2021 0.47 [0.04; 5.45] Sekine (PLACOVID), 2021 2.14 [0.70; 6.58] 0.82[0.42; 1.61]ConPlas-19, 2020, DAWN-Plasma, 2021, NCT04397757, 2021, Sekine (PLACOVID), 2021424%1,072moderatenot evaluable death D28detailed resultsAlQahtani, 2020 0.47 [0.04; 5.69] ASCOT, 2021 0.60 [0.06; 5.99] Bennett-Guerrero, 2021 0.86 [0.24; 3.11] Co-CLARITY, 2021 0.92 [0.02; 50.28] CONCOR-1, 2021 1.12 [0.86; 1.46] ConPlas-19, 2020 0.49 [0.20; 1.19] CONTAIN COVID-19, 2021 0.86 [0.60; 1.25] COPLA-II trial, 2020 1.17 [0.72; 1.92] DAWN-Plasma, 2021 0.99 [0.52; 1.88] ITAC, 2022 0.80 [0.42; 1.52] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Kirenga, 2021 1.25 [0.46; 3.39] Li, 2020 0.59 [0.22; 1.59] LIFESAVER, 2021 2.00 [0.16; 24.66] Menichetti, 2021 0.75 [0.37; 1.53] NCT04397757, 2021 0.15 [0.03; 0.75] NCT04403477 (two doses), 2021 0.53 [0.14; 2.01] NCT04528368, 2021 0.88 [0.02; 50.20] O’Donnell, 2021 0.47 [0.21; 1.06] Pandit, 2021 0.95 [0.02; 50.33] PC/COVID-19, 2021 0.63 [0.11; 3.58] PERUCONPLASMA, 2021 0.36 [0.04; 3.13] PlasmAr, 2020 0.93 [0.47; 1.85] Pouladzadeh, 2021 0.31 [0.01; 10.20] Raman, 2021 0.49 [0.02; 15.10] RECOVER, 2021 1.09 [0.38; 3.13] RECOVERY (plasma), 2021 1.00 [0.93; 1.07] RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91] Sakoulas, 2020 0.29 [0.03; 3.13] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] Shashi Bhushan, 2021 4.39 [0.20; 98.33] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] Tabarsi, 2020 1.10 [0.45; 2.67] 0.91[0.83; 0.99]AlQahtani, 2020, ASCOT, 2021, Bennett-Guerrero, 2021, Co-CLARITY, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COPLA-II trial, 2020, DAWN-Plasma, 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Kirenga, 2021, Li, 2020, LIFESAVER, 2021, Menichetti, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04528368, 2021, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, RECOVER, 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Tabarsi, 2020338%23,071moderatecritical death or transfer to ICUdetailed resultsLopardo, 2021 0.65 [0.35; 1.22] 0.65[0.35; 1.22]Lopardo, 202110%241NAnot evaluable deathsdetailed resultsACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17] ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97] ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21] AlQahtani, 2020 0.47 [0.04; 5.69] ASCOT, 2021 0.60 [0.06; 5.99] Baldeon, 2022 1.85 [0.49; 6.97] Bennett-Guerrero, 2021 0.80 [0.26; 2.45] CAPSID, 2021 0.84 [0.28; 2.50] CCAP-2, 2021 2.03 [0.61; 6.77] Co-CLARITY, 2021 0.92 [0.02; 50.28] CONCOR-1, 2021 1.02 [0.77; 1.36] ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59] CONFIDENT, 2020 0.84 [0.52; 1.37] ConPlas-19, 2020 0.46 [0.19; 1.15] CONTAIN COVID-19, 2021 0.86 [0.60; 1.25] COP-COVID-19, 2021 0.96 [0.36; 2.56] COPLA-II trial, 2020 1.17 [0.72; 1.92] CP-COVID-19, 2021 3.20 [0.62; 16.39] Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25] Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92] DAWN-Plasma, 2021 0.99 [0.52; 1.88] Fu, 2020 1.00 [0.02; 51.66] Holm K, 2021 0.49 [0.08; 2.89] ITAC, 2022 0.80 [0.42; 1.52] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Kirenga, 2021 1.25 [0.46; 3.39] Li, 2020 0.59 [0.22; 1.59] Libster, 2020 0.50 [0.09; 2.71] LIFESAVER, 2021 2.00 [0.16; 24.66] Lopardo, 2021 0.57 [0.24; 1.37] Menichetti, 2021 0.75 [0.37; 1.53] NCT04385199, 2021 0.75 [0.15; 3.77] NCT04397757, 2021 0.15 [0.03; 0.75] NCT04403477 (two doses), 2021 0.53 [0.14; 2.01] NCT04442191, 2021 0.11 [0.00; 143.68] NCT04528368, 2021 0.88 [0.02; 50.20] O’Donnell, 2021 0.47 [0.21; 1.06] Pandit, 2021 0.95 [0.02; 50.33] PC/COVID-19, 2021 0.63 [0.11; 3.58] PERUCONPLASMA, 2021 0.36 [0.04; 3.13] PlasmAr, 2020 0.93 [0.47; 1.85] Pouladzadeh, 2021 0.31 [0.01; 10.20] Rahmani, 2020 0.29 [0.05; 1.56] Raman, 2021 0.49 [0.02; 15.10] Rasheed, 2020 0.13 [0.01; 1.09] RECOVER, 2021 1.09 [0.38; 3.13] RECOVERY (plasma), 2021 1.00 [0.93; 1.07] RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91] REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15] Sakoulas, 2020 0.29 [0.03; 3.13] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] Shashi Bhushan, 2021 4.39 [0.20; 98.33] SOLIDARITY (interferon), 2020 1.16 [0.96; 1.40] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] Synairgen SG016, 2020 0.16 [0.01; 3.31] Tabarsi, 2020 1.10 [0.45; 2.67] 0.91[0.84; 0.98]ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, AlQahtani, 2020, ASCOT, 2021, Baldeon, 2022, Bennett-Guerrero, 2021, CAPSID, 2021, CCAP-2, 2021, Co-CLARITY, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COP-COVID-19, 2021, COPLA-II trial, 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, DAWN-Plasma, 2021, Fu, 2020, Holm K, 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Kirenga, 2021, Li, 2020, Libster, 2020, LIFESAVER, 2021, Lopardo, 2021, Menichetti, 2021, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04442191, 2021, NCT04528368, 2021, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, Rasheed, 2020, RECOVER, 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, REMAP-CAP (plasma), 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, SOLIDARITY (interferon), 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020, Tabarsi, 2020569%33,045moderatecritical deaths (time to event analysis only)detailed resultsACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17] ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97] Baldeon, 2022 1.85 [0.49; 6.97] Bennett-Guerrero, 2021 0.80 [0.26; 2.45] CONCOR-1, 2021 1.02 [0.77; 1.36] ConPlas-19, 2020 0.46 [0.19; 1.15] CP-COVID-19, 2021 3.20 [0.62; 16.39] DAWN-Plasma, 2021 0.99 [0.52; 1.88] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] PlasmAr, 2020 0.93 [0.47; 1.85] 0.91[0.74; 1.11]ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, Baldeon, 2022, Bennett-Guerrero, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CP-COVID-19, 2021, DAWN-Plasma, 2021, Kalil (ACTT-3), 2021, PlasmAr, 2020108%5,192moderatelow clinical deteriorationdetailed resultsCAPSID, 2021 0.63 [0.29; 1.40] ConPlas-19, 2020 1.00 [0.65; 1.53] CONTAIN COVID-19, 2021 0.94 [0.75; 1.18] Kirenga, 2021 0.91 [0.38; 2.17] Libster, 2020 0.52 [0.29; 0.94] Synairgen SG016, 2020 0.50 [0.18; 1.38] 0.84[0.69; 1.04]CAPSID, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, Kirenga, 2021, Libster, 2020, Synairgen SG016, 2020610%1,458moderatenot evaluable clinical improvementdetailed resultsACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20] ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29] Bennett-Guerrero, 2021 0.75 [0.21; 2.68] CAPSID, 2021 1.58 [0.71; 3.49] ConPlas-19, 2020 0.95 [0.60; 1.52] Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] ITAC, 2022 1.06 [0.77; 1.45] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Li, 2020 1.40 [0.79; 2.49] Lopardo, 2021 1.61 [0.75; 3.49] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 0.81 [0.50; 1.31] Pouladzadeh, 2021 7.31 [1.62; 32.97] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] Shashi Bhushan, 2021 0.68 [0.21; 2.20] Synairgen SG016, 2020 2.32 [1.07; 5.04] 1.08[0.96; 1.22]ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, Bennett-Guerrero, 2021, CAPSID, 2021, ConPlas-19, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Li, 2020, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Synairgen SG016, 20201636%4,947moderatelow clinical improvement (14-day)detailed resultsKalil (ACTT-3), 2021 1.01 [0.79; 1.29] Li, 2020 2.27 [0.90; 5.72] Pandit, 2021 8.77 [0.94; 81.67] Shashi Bhushan, 2021 0.68 [0.21; 2.20] 1.37[0.69; 2.72]Kalil (ACTT-3), 2021, Li, 2020, Pandit, 2021, Shashi Bhushan, 2021456%1,353moderatenot evaluable clinical improvement (28-day)detailed resultsBennett-Guerrero, 2021 1.02 [0.25; 4.20] Li, 2020 1.42 [0.65; 3.10] O’Donnell, 2021 1.38 [0.73; 2.61] Pouladzadeh, 2021 7.31 [1.62; 32.97] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] Synairgen SG016, 2020 3.15 [1.39; 7.14] 1.61[0.96; 2.70]Bennett-Guerrero, 2021, Li, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Synairgen SG016, 2020667%721moderateserious clinical improvement (7-day)detailed resultsACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29] ITAC, 2022 1.06 [0.77; 1.45] Li, 2020 0.98 [0.27; 3.58] Shashi Bhushan, 2021 1.91 [1.03; 3.53] 1.10[0.80; 1.51]ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022, Li, 2020, Shashi Bhushan, 2021435%1,224moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsBennett-Guerrero, 2021 0.75 [0.21; 2.68] ConPlas-19, 2020 0.95 [0.60; 1.52] Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Li, 2020 1.40 [0.79; 2.49] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 1.00 [0.76; 1.32] Rahmani, 2020 3.41 [1.33; 8.73] 1.16[0.96; 1.40]Bennett-Guerrero, 2021, ConPlas-19, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Kalil (ACTT-3), 2021, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020942%1,930moderateserious death or ventilationdetailed resultsCONCOR-1, 2021 1.16 [0.94; 1.43] ConPlas-19, 2020 0.94 [0.86; 1.02] DAWN-Plasma, 2021 1.01 [0.64; 1.59] Menichetti, 2021 0.88 [0.59; 1.32] RECOVERY (plasma), 2021 0.99 [0.93; 1.05] RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92] SOLIDARITY (interferon), 2020 1.05 [0.90; 1.23] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94] Synairgen SG016, 2020 0.38 [0.09; 1.63] 0.94[0.87; 1.03]CONCOR-1, 2021, ConPlas-19, 2020, DAWN-Plasma, 2021, Menichetti, 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, SOLIDARITY (interferon), 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020959%21,562moderatenot evaluable hospital dischargedetailed resultsACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20] ConPlas-19, 2020 1.02 [0.82; 1.28] DAWN-Plasma, 2021 1.06 [0.87; 1.30] Rahmani, 2020 3.44 [0.64; 18.49] RECOVERY (plasma), 2021 0.99 [0.92; 1.07] RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09] Synairgen SG016, 2020 1.63 [0.61; 4.35] 1.09[0.98; 1.21]ACTIV-3/TICO LY-CoV555 , 2020, ConPlas-19, 2020, DAWN-Plasma, 2021, Rahmani, 2020, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020855%17,222moderatenot evaluable hospitalizationdetailed resultsJagannathan, 2020 1.00 [0.14; 7.34] 1.00[0.14; 7.34]Jagannathan, 202010%120NAnot evaluable mechanical ventilationdetailed resultsAlQahtani, 2020 0.67 [0.22; 2.02] COPLA-II trial, 2020 0.58 [0.37; 0.92] Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67] Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67] Holm K, 2021 0.39 [0.01; 12.68] NCT04397757, 2021 0.41 [0.13; 1.35] O’Donnell, 2021 1.50 [0.47; 4.82] PlasmAr, 2020 0.86 [0.39; 1.93] Rahmani, 2020 0.29 [0.05; 1.56] RECOVERY (plasma), 2021 0.98 [0.88; 1.09] Sakoulas, 2020 0.19 [0.03; 1.11] Tabarsi, 2020 1.49 [0.59; 3.78] 0.82[0.64; 1.06]AlQahtani, 2020, COPLA-II trial, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Holm K, 2021, NCT04397757, 2021, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, RECOVERY (plasma), 2021, Sakoulas, 2020, Tabarsi, 20201221%12,311moderatecritical mechanical ventilation (time to event analysis only)detailed resultsCP-COVID-19, 2021 0.66 [0.25; 1.72] DAWN-Plasma, 2021 1.08 [0.65; 1.80] 0.97[0.62; 1.52]CP-COVID-19, 2021, DAWN-Plasma, 202120%583moderatenot evaluable radiologic improvement (14-day)detailed resultsTabarsi, 2020 2.33 [0.45; 12.00] 2.33[0.45; 12.00]Tabarsi, 202010%84NAnot evaluable viral clearance detailed resultsCP-COVID-19, 2021 1.12 [0.16; 7.84] Jagannathan, 2020 0.81 [0.56; 1.18] Pandit, 2021 2.33 [0.55; 9.83] Raman, 2021 36.42 [10.85; 122.18] Salman, 2020 1.00 [0.02; 53.89] Shashi Bhushan, 2021 2.77 [1.44; 5.32] 2.71[0.82; 8.92]CP-COVID-19, 2021, Jagannathan, 2020, Pandit, 2021, Raman, 2021, Salman, 2020, Shashi Bhushan, 2021688%631moderatenot evaluable viral clearance (time to event analysis only)detailed resultsJagannathan, 2020 0.81 [0.56; 1.18] 0.81[0.56; 1.18]Jagannathan, 202010%120NAnot evaluable viral clearance by day 14detailed resultsCP-COVID-19, 2021 1.51 [0.33; 6.94] Kirenga, 2021 0.95 [0.76; 1.19] Pandit, 2021 10.23 [1.12; 93.35] Raman, 2021 36.42 [10.85; 122.18] Shashi Bhushan, 2021 0.00 [0.00; 0.01] 1.08[0.07; 16.52]CP-COVID-19, 2021, Kirenga, 2021, Pandit, 2021, Raman, 2021, Shashi Bhushan, 2021597%1,684moderatenot evaluable viral clearance by day 7detailed resultsKirenga, 2021 0.87 [0.65; 1.16] Pandit, 2021 2.33 [0.55; 9.83] Salman, 2020 1.00 [0.02; 53.89] Shashi Bhushan, 2021 2.77 [1.44; 5.32] 1.59[0.67; 3.76]Kirenga, 2021, Pandit, 2021, Salman, 2020, Shashi Bhushan, 2021473%439moderatenot evaluable ICU admissiondetailed resultsCP-COVID-19, 2021 0.82 [0.35; 1.91] Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71] Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94] Libster, 2020 0.33 [0.07; 1.58] Lopardo, 2021 0.67 [0.35; 1.28] Rahmani, 2020 0.37 [0.14; 1.00] Tabarsi, 2020 0.56 [0.18; 1.74] 0.60[0.41; 0.88]CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Libster, 2020, Lopardo, 2021, Rahmani, 2020, Tabarsi, 202070%731moderatenot evaluable recoverydetailed resultsACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32] ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37] ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46] Synairgen SG016, 2020 2.19 [1.03; 4.67] 1.12[0.97; 1.28]ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, Synairgen SG016, 202047%1,129lownot evaluable composite safety outcome detailed resultsACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11] 1.56[0.78; 3.11]ACTIV-3/TICO LY-CoV555 , 202010%314NAnot evaluable serious adverse eventsdetailed resultsCONCOR-1, 2021 1.27 [1.02; 1.58] ConPlas-19, 2020 0.89 [0.43; 1.86] ITAC, 2022 0.98 [0.66; 1.46] Jagannathan, 2020 1.00 [0.14; 7.34] O’Donnell, 2021 0.64 [0.35; 1.17] Pandit, 2021 0.95 [0.02; 50.33] PlasmAr, 2020 1.40 [0.78; 2.51] Raman, 2021 0.49 [0.02; 15.10] REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46] Sekine (PLACOVID), 2021 1.14 [0.88; 1.48] 1.16[0.98; 1.36]CONCOR-1, 2021, ConPlas-19, 2020, ITAC, 2022, Jagannathan, 2020, O’Donnell, 2021, Pandit, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 20211012%4,802moderatelow superinfectiondetailed resultsRahmani, 2020 0.18 [0.02; 1.59] 0.18[0.02; 1.59]Rahmani, 202010%66NAnot evaluable adverse eventsdetailed resultsJagannathan, 2020 1.33 [0.63; 2.78] Kirenga, 2021 1.13 [0.50; 2.58] Pandit, 2021 1.68 [0.47; 5.97] Raman, 2021 1.36 [0.56; 3.30] Sakoulas, 2020 1.00 [0.02; 53.46] Sekine (PLACOVID), 2021 1.08 [0.85; 1.38] 1.13[0.91; 1.40]Jagannathan, 2020, Kirenga, 2021, Pandit, 2021, Raman, 2021, Sakoulas, 2020, Sekine (PLACOVID), 202160%589moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-03-29 00:20 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567 - roots T: 290